Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BIOR NYSE:CANF NASDAQ:GLMD NASDAQ:SPRC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIORBiora Therapeutics$0.15+6.5%$0.14$0.15▼$7.10$660K1.1286,634 shs16,292 shsCANFCan-Fite BioPharma$0.63-4.8%$0.85$0.63▼$3.12$2.24M1.02208,153 shs146,374 shsGLMDGalmed Pharmaceuticals$1.27-8.0%$1.71$1.15▼$23.80$2.28M0.58237,229 shs180,817 shsSPRCSciSparc$2.46-18.8%$6.03$2.43▼$37.59$1.62M0.88902,810 shs604,924 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIORBiora Therapeutics0.00%0.00%0.00%+2.75%-97.84%CANFCan-Fite BioPharma-0.60%-1.05%-7.64%-38.70%-71.30%GLMDGalmed Pharmaceuticals-0.72%-6.12%-22.91%-4.17%-57.09%SPRCSciSparc-28.87%-28.37%-54.71%-54.53%-65.99%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBIORBiora Therapeutics1.9528 of 5 stars3.50.00.00.00.62.50.6CANFCan-Fite BioPharma1.5588 of 5 stars3.52.00.00.00.00.01.3GLMDGalmed Pharmaceuticals1.7177 of 5 stars0.05.00.00.02.22.50.6SPRCSciSparc1.0097 of 5 stars0.05.00.00.02.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIORBiora Therapeutics 3.00Buy$23.0015,664.22% UpsideCANFCan-Fite BioPharma 3.00Buy$14.002,117.29% UpsideGLMDGalmed Pharmaceuticals 2.00HoldN/AN/ASPRCSciSparc 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BIOR, GLMD, CANF, and SPRC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/29/2025CANFCan-Fite BioPharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIORBiora Therapeutics$892K0.74N/AN/A($36.43) per share0.00CANFCan-Fite BioPharma$674K3.32N/AN/A$1.76 per share0.36GLMDGalmed PharmaceuticalsN/AN/AN/AN/A$9.87 per shareN/ASPRCSciSparc$1.31M1.00N/AN/A$18.13 per share0.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIORBiora Therapeutics-$124.11M-$13.04N/AN/AN/AN/AN/A-332.47%N/ACANFCan-Fite BioPharma-$7.63M-$1.79N/AN/AN/AN/AN/AN/AN/AGLMDGalmed Pharmaceuticals-$7.52M-$16.66N/A∞N/AN/A-21.68%-19.26%11/12/2025 (Estimated)SPRCSciSparc-$6.28MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBIORBiora TherapeuticsN/AN/AN/AN/AN/ACANFCan-Fite BioPharmaN/AN/AN/AN/AN/AGLMDGalmed PharmaceuticalsN/AN/AN/AN/AN/ASPRCSciSparcN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIORBiora TherapeuticsN/A0.050.05CANFCan-Fite BioPharmaN/A2.93N/AGLMDGalmed PharmaceuticalsN/A9.029.02SPRCSciSparcN/A5.365.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIORBiora Therapeutics43.74%CANFCan-Fite BioPharma21.00%GLMDGalmed Pharmaceuticals76.14%SPRCSciSparc25.06%Insider OwnershipCompanyInsider OwnershipBIORBiora Therapeutics51.08%CANFCan-Fite BioPharma0.80%GLMDGalmed Pharmaceuticals19.80%SPRCSciSparc1.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBIORBiora Therapeutics1204.52 million2.21 millionOptionableCANFCan-Fite BioPharma83.54 millionN/ANot OptionableGLMDGalmed Pharmaceuticals201.65 million1.33 millionNot OptionableSPRCSciSparc4530,000527,000Not OptionableBIOR, GLMD, CANF, and SPRC HeadlinesRecent News About These CompaniesSciSparc Shareholders Approve Merger with AutoMaxAugust 28 at 4:31 PM | tipranks.comSciSparc: AutoMax's Shareholders Approve Merger with SciSparcAugust 28 at 9:24 AM | globenewswire.comSciSparc Ltd. Shareholders Approve Merger with AutoMax Motors Ltd. to Expand into Automotive SectorAugust 28 at 6:51 AM | quiverquant.comQSciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in IsraelAugust 28 at 6:45 AM | globenewswire.comSciSparc Shareholders Approve Key Proposals at August MeetingAugust 26 at 12:27 AM | msn.comSciSparc (NASDAQ:SPRC) Stock Price Down 8.9% - Here's What HappenedAugust 26 at 2:30 AM | americanbankingnews.comSciSparc Ltd. Reschedules Special Shareholder Meeting Due to Lack of QuorumAugust 25, 2025 | tipranks.comSciSparc Announces Patent Filing and Merger UpdatesAugust 8, 2025 | theglobeandmail.comSciSparc and Clearmind Publish Patent for Novel Obesity TherapyAugust 8, 2025 | tipranks.comSciSparc Ltd. and Clearmind Medicine Inc. Collaborate to Launch International Patent Application for Innovative Therapy Targeting Metabolic Syndrome and ObesityAugust 7, 2025 | quiverquant.comQSciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood SugarAugust 7, 2025 | globenewswire.comSciSparc Ltd: SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SECJuly 31, 2025 | finanznachrichten.deSciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SECJuly 30, 2025 | globenewswire.comClearmind Medicine files international patent application under PCTJuly 30, 2025 | msn.comSciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver DiseaseJuly 30, 2025 | globenewswire.comSciSparc Ltd. Regains Nasdaq ComplianceJuly 22, 2025 | tipranks.comSciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price NotificationJuly 22, 2025 | globenewswire.comSciSparc Announces 1-for-21 Reverse Share Split - MorningstarJune 26, 2025 | morningstar.comMSciSparc Ltd. Adjourns Annual Meeting Due to Lack of QuorumJune 25, 2025 | msn.comSciSparc Ltd: SciSparc Announces 1-for-21 Reverse Share SplitJune 25, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBIOR, GLMD, CANF, and SPRC Company DescriptionsBiora Therapeutics NASDAQ:BIORBiora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.Can-Fite BioPharma NYSE:CANF$0.63 -0.03 (-4.84%) Closing price 03:59 PM EasternExtended Trading$0.64 +0.01 (+2.15%) As of 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.Galmed Pharmaceuticals NASDAQ:GLMD$1.27 -0.11 (-7.97%) Closing price 03:59 PM EasternExtended Trading$1.32 +0.04 (+3.54%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.SciSparc NASDAQ:SPRC$2.46 -0.57 (-18.81%) Closing price 04:00 PM EasternExtended Trading$2.48 +0.02 (+0.61%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access